Monitor the next 10-Q filing for disclosure of the full separation agreement and any impact on compensation expenses. The departure of a financial officer warrants attention, but the orderly transition and lack of immediate replacement suggest a manageable transition.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 27 $19.10entry
- T+1 · 7mo ago 0.00%α +0.49% · $19.10
- T+5 · 7mo ago +11.15%α +10.75% · $21.23
- T+20 · 6mo ago +27.02%α +22.06% · $24.26
- T+60 · 4mo ago +1.47%α −3.31% · $19.38
Price Chart
How similar events traded
Executive Summary
NewAmsterdam Pharma's Chief Accounting Officer, Louise Kooij, will depart on August 31, 2026, with a separation agreement providing 12 months of base salary, a pro-rated bonus, and extended vesting of equity awards through January 2027. The departure appears planned and orderly.
Key Facts
- Chief Accounting Officer Louise Kooij is departing effective August 31, 2026
- Departure was mutually agreed upon and not unexpected
- Separation agreement includes 12 months of base salary, pro-rated 2026 bonus, and accrued vacation
- Equity vesting extended through January 10, 2027, with exercise period until February 10, 2027
- No replacement has been announced
Financial Impact
Approximately 12 months of base salary plus pro-rated bonus (exact dollar amounts undisclosed)
Risk Factors
- Potential disruption in financial reporting during transition
- Increased workload for remaining finance team
- Uncertainty around succession planning for key financial roles
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-177406 |
| Document: 0001193125-26-177406-index-headers.html | 0001193125-26-177406 |
| Document: 0001193125-26-177406-index.html | 0001193125-26-177406 |
| Document: 0001193125-26-177406.txt | 0001193125-26-177406 |
Track record
3 reports on NAMSW
The track record builds as more bullish or bearish reports settle.
Filters
- Jun 3, 202623w ago 8-K Neutral 3/10 Entry $24.90 to $16.51 Now $9.49 −61.88% ▼ −33.68% −36.18% vs SPY
- May 7, 202627w ago 8-K Bullish 6/10 Entry $22.80 to $15.00 Now $9.49 −58.38% ▼ −34.21% −38.04% vs SPY
- Apr 24, 202629w ago 8-K Neutral 3/10 Viewing Entry $19.10 to $19.38 Now $9.49 −50.31% ▲ +1.47% −3.31% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers